Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG)

摘要: Abstract Background CMs are products used concurrently with conventional medicine, including natural and homeopathy. CM use is prevalent amongst cancer patients, but the in patients enrolled on P3T had yet to be studied. This study examined patient characteristics outcomes of users conducted by CCTG. Methods Data were acquired from six international included metastatic breast (BR), colorectal (CRC), non-small-cell lung cancers (LC) (MA.31, CO.17, 20 &23, BR.21 &26). Medications independently reviewed two authors identify CM; discrepancies a third author, final list was approved consensus. Patient associated identified Chi-square logistic regression. Propensity score stratification compare between non-users for overall survival (OS), grade 3+ adverse events (AE) quality life (QOL) scales (EORTC-QLQ-C30). Results 3446 (17.7% BR, 44.4% CRC, 37.8% LC). Of 24908 medications, 651 (2.6%) considered 20.4% users. LC (p  Conclusions The high. Patient’s using tend younger have better PS. Worse QOL indices use, although time deterioration incidence AE not. HR OS trials favoured users, however, this should interpreted caution given retrospective/post-hoc nature more favourable baseline characteristics. Clinical trial identification MA.31- NCT00667251 CO.17- NCT00079066 CO.20- NCT00640471 CO.23- NCT01830621 BR.21- NCT00036647 BR.26- NCT01000025. Legal entity responsible authors. Funding Has not received any funding. Disclosure P.A. Bradbury: Honoraria (self), Advisory / Consultancy: AbbVie; BI; Merck; (self): Lilly. C. Karapetis: Merck Serono. L.K. Seymour: Research grant (institution): Pfizer; OSI Pharmaceuticals. All other declared no conflicts interest.